| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 13,120 | 4,833 | 3,084 | 727 |
| Cost of revenue | 3,349 | 2,576 | 2,094 | 1,515 |
| Gross profit (deficit) | 9,771 | 2,257 | 990 | -788 |
| Research and development | 28,846 | 27,362 | 24,601 | 27,731 |
| Acquired in-process research and development | 0 | 0 | - | - |
| Selling, general and administrative | 37,359 | 38,484 | 35,393 | 19,582 |
| Total operating expenses | 66,205 | 65,846 | 59,994 | 47,313 |
| Loss from operations | -56,434 | -63,589 | -59,004 | -48,101 |
| Interest income | 6,033 | 4,780 | 5,321 | 6,726 |
| Interest expense | 6,534 | 421 | 54 | 120 |
| Investment advisory fees | 171 | 182 | 203 | 237 |
| Change in fair value of warrant liability | -612 | -454 | 751 | -533 |
| Realized (loss) gain on marketable securities | 0 | -1 | 3 | -11 |
| Net gain (loss) on disposal of fixed assets | 4 | -34 | - | - |
| Other income | 698 | -14 | 1,452 | - |
| Total other income, net | 642 | 4,582 | 5,768 | 6,891 |
| Loss before income taxes | -55,792 | -59,007 | -53,236 | -41,210 |
| Provision for income taxes | 0 | 0 | - | - |
| Net loss | -55,792 | -59,007 | -53,236 | -41,210 |
| Currency translation adjustment | 313 | 646 | -465 | - |
| Change in unrealized gain (loss) on available-for-sale securities | 501 | -225 | -493 | - |
| Comprehensive loss | -55,604 | -59,878 | -53,264 | - |
| Net loss per share attributable to common stockholders, basic | -0.16 | -0.17 | -0.16 | -0.15 |
| Net loss per share attributable to common stockholders, diluted | -0.16 | -0.17 | -0.16 | -0.15 |
| Weighted average common shares outstanding, basic | 342,393 | 340,746 | 338,612 | 273,565 |
| Weighted average common shares outstanding, diluted | 342,393 | 340,746 | 338,612 | 273,565 |
Nuvation Bio Inc. (NUVB)
Nuvation Bio Inc. (NUVB)